Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
16 hedge funds and large institutions have $7.21M invested in Vyant Bio, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
+$1.48M |
| 2 |
SCM
Sterneck Capital Management
Kansas City,
Missouri
|
+$837K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$515K |
| 4 |
Jane Street
New York
|
+$315K |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$188K |
Top Sellers
VYNT Hedge Fund Activity: Q3 2013 in Review
16 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q3 2013, worth a combined $7.21M.
Buyers outnumbered sellers: 16 funds opened new VYNT positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Timpani Capital Management, opening a new position worth an estimated $1.48M.
- 16 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q3 2013, up from 0 in Q2 2013.
- Funds reported $7.21M of Vyant Bio, Inc. Common Stock stock for Q3 2013.
- 16 funds opened new Vyant Bio, Inc. Common Stock positions in Q3 2013 and 0 closed out, a net change of +16 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q3 2013 was Timpani Capital Management, an estimated $1.48M added.
Based on aggregated 13F filings for Q3 2013.